Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Published Time:
2024-10-23 17:49
Source:
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
Following its inclusion in the 2022 list, Jiangsu Vcare's reappearance in 2024 reflects the industry's full recognition of its innovation strength. Since inception, Jiangsu Vcare has prioritized innovation as its core driver, continuously advancing technological transformation. In recent years, the company has significantly increased R&D investment, recruited top talent, and procured internationally advanced equipment, demonstrating unwavering commitment to innovation.
Jiangsu Vcare has established cutting-edge technology platforms—including AI molecular generation, drug screening, crystal/salt form selection, and novel formulations—focusing precisely on therapeutic areas such as cardiovascular, oncology, inflammation, and autoimmune diseases. Currently, it has5 clinical-stage Class I innovative drug projectsand over10 preclinical projectsunder development, forming a diversified, high-potential R&D pipeline.
Moving forward, Jiangsu Vcare will adhere to its innovation-driven and globalized strategy, targeting frontier technologies and unmet clinical needs to develop breakthrough therapeutics, contributing "Vcare Power" to global health.
Related News
16
2021
/
08
Jiangsu Vcare's Class 1 Innovative Drug VC005 Tablets Receives Clinical Trial Approval
In August 2021, VC005 tablets, an innovative drug developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received clinical trial approval from the NMPA for the indication of inflammatory bowel disease (IBD), with clinical trials set to begin shortly.
View Details
29
2021
/
07
Jiangsu Vcare Secures New Round of Financing Totaling CNY 100 Million
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) secures another strategic investment of CNY 100 million. This round was jointly invested by Nanjing NII Group, Renpu Capital, and Nanjing Innovation Capital Group. The funds will primarily be used to advance the clinical research of innovative drug pipeline projects like Vicagrel and VC004, while accelerating strategic layout in the CDMO business sector.
View Details
24
2021
/
06
Vcare Pharmatech Selected as 2021 Nanjing Nurtured Unicorn Enterprise
On June 23, 2021, the list of Nanjing Unicorn and Gazelle Enterprises was announced. Jiangsu Vcare Pharmatech Technology Co., Ltd.(Vcare Pharmatech) was selected as a 2021 Nanjing Nurtured Unicorn Enterprise.
View Details
22
2021
/
03
Jiangsu Vcare's Novel Drug Vicagrel Receives FDA Approval for Clinical Trials
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced encouraging news regarding its novel antiplatelet drug Vicagrel: The US FDA has provided feedback on the company's submitted IND application for Vicagrel, permitting the company to initiate clinical trials.
View Details
12
2021
/
03
Jiangsu Vcare Completes Pre-IND Submission for VC005, a Highly Selective JAK1 Inhibitor New Drug
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a Pre-IND application to the NMPA for its VC005 tablets. VC005 is a highly selective JAK1 inhibitor independently designed by Jiangsu Vcare. It is intended for the clinical treatment of inflammatory bowel disease (IBD), an intestinal autoimmune disorder.
View Details
08
2021
/
03
Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Financing Round
Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) has secured financing worth hundreds of millions of CNY in a round led by SDIC Capital, with participation from Fengling Capital. The funds will accelerate Vcare’s CDMO expansion and Phase III clinical research for its innovative drug Vicagrel.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn